BOSTON – There is no doubt that 3D bioprinting is a technology of the future. Imagine being able to print a kidney or liver on demand. This is a stark contrast to the long wait for a donor organ today.
Currently, the average wait time for a liver is 4 to 5 months and 2.5 to 3 years for a kidney in the U.K. Despite the acceleration in 3D bioprinting research we have witnessed in the past few years, we are still far from the holy grail of printed organs for transplant.
To learn more about 3D bioprinting and the market forecast for 2028, please refer to the IDTechEx report “3D bioprinting 2018-2028: Technologies, Markets, Forecast.”
The problem with today’s 3D bioprinted organs is that they are limited by size. Scientists can manipulate cells to grow into mini organs by placing different types of cells in specific locations, or even using stem cells and letting nature take its course, but as yet, these structures are very small. This is because scientists have yet to figure out how to create the complicated network of blood vessels within organs that are needed to feed cells with essential nutrition and oxygen. Instead, most of the structures printed today have either very basic vasculature, which is not adequate for sustaining large organs, or they are thin enough to simply rely on diffusion forces.
Despite the small size of the 3D bioprinted tissue today, which makes them less clinically relevant, these tissue structures can be used for research purposes. Small tissues that mimic their larger counterparts can be used to test chemicals for human use, such as pharmaceuticals.
In IDTechEx’s 10-year market forecast, we have predicted that companies selling into this market will capture the majority of the $1.9 billion value. For more information, please refer to the report “3D bioprinting 2018-2028: Technologies, Markets, Forecast.”
Testing drugs on 3D bioprinted organs has the potential to optimize and accelerate the drug development process. The greatest impact will be in eliminating toxic drugs more quickly so that they do not make it to the costly clinical trials process. This way, resources can be focused on more promising opportunities, and human volunteers will be exposed to lowered risks.
With 3D bioprinted models, new avenues are also opened. For example, the creation of mini brain organoid models, or the modeling of the human blood-brain barrier, can help researchers better understand how the brain works and work to develop drugs for brain disorders such as Alzheimer’s disease and deadly cancers such as glioblastoma.
There is still a ways to go in developing 3D bioprinting technologies before they are ready to create 3D bioprinted organs for transplant. IDTechEx does not foresee the regenerative medicine market to contribute substantially to the overall value provided by 3D bioprinting by the year 2028. For now, we are optimistic that 3D bioprinted organ models will lead researchers to a better understanding of human biology and disease, which will lead us to better therapeutics.